Sign in to view content

3-Year Update for the Phase 3 Voretigene Neparvovecrzyl Study in Biallelic RPE65 Mutation–Associated Inherited Retinal Disease

Stephen R. Russell, MD

Video
Published 2018

Related

Robotic Surgery as a Delivery Tool for Novel Retinal Therapies
Lyndon da Cruz, MBBS, BA, MA, FRCOphth, PhD, FRACO
Updates from the Field
2019
Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Updates from the Field
2021
Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years
Stephen R. Russell, MD
Annual Meeting Talks
2024

Category: Hereditary Retinal Disease & Genetics

See more